Anthera Pharmaceuticals, Inc.
ANTH
ANTH was delisted on the 27th of June, 2018.
72 hedge funds and large institutions have $67M invested in Anthera Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 7 closing their positions.
47% more call options, than puts
Call options by funds: $738K | Put options by funds: $502K
4% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 23
5% less capital invested
Capital invested by funds: $70.5M → $67M (-$3.48M)
3% less funds holding
Funds holding: 74 → 72 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$806K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$520K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$360K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$259K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$239K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$5.15M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$463K |
| 3 |
State Street
Boston,
Massachusetts
|
-$278K |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$254K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$254K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Dimensional Fund Advisors
Austin,
Texas
| – | -$89K | -3,595 | Closed |
|
|
BFM
77
Boothbay Fund Management
New York
| – | -$49K | -1,995 | Closed |
|
78
JP Morgan Chase
New York
| – | -$7K | -266 | Closed |
|
ANTH Hedge Fund Activity: Q3 2016 in Review
72 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Anthera Pharmaceuticals, Inc. (ANTH) for Q3 2016, worth a combined $67M — down 4.9% from $70.5M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ANTH and 5 opened new positions — a net loss of 2 holders — while 23 trimmed existing stakes and 24 added.
The largest buyer was D.A. Davidson & Co, adding an estimated $806K. The largest seller was Sio Capital Management, cutting an estimated $5.15M.
- 72 institutional investors held Anthera Pharmaceuticals, Inc. (ANTH) as of Q3 2016, down from 74 in Q2 2016.
- Funds reported $67M of Anthera Pharmaceuticals, Inc. stock for Q3 2016, down 4.9% quarter-over-quarter.
- 5 funds opened new Anthera Pharmaceuticals, Inc. positions in Q3 2016 and 7 closed out, a net change of -2 holders.
- The largest Anthera Pharmaceuticals, Inc. buyer in Q3 2016 was D.A. Davidson & Co, an estimated $806K added.
- The largest Anthera Pharmaceuticals, Inc. seller in Q3 2016 was Sio Capital Management, an estimated $5.15M sold.
Based on aggregated 13F filings for Q3 2016.